Lipanthyl Supra (Fenofibrate)

Fenofibrate activates the nuclear receptor PPARα, leading to increased fatty‑acid oxidation, reduced hepatic VLDL production, and enhanced HDL synthesis, collectively lowering triglycerides and improving overall lipid profiles.

The specific dose of Lipanthyl Supra is determined by the prescribing clinician based on the patient’s medical condition, laboratory results, and response to therapy. Dosage should never be adjusted without professional guidance.

Safety data for fenofibrate in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Lipanthyl Supra, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with statins, fenofibrate primarily lowers triglycerides and raises HDL, while statins mainly reduce LDL‑cholesterol. Fenofibrate may be combined with statins for broader lipid control, but clinicians monitor for increased risk of muscle‑related side effects.

Store Lipanthyl Supra at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Lipanthyl Supra is taken orally, usually with a meal to enhance absorption. Patients should follow the prescribing physician’s instructions regarding timing, food intake, and whether the tablet should be swallowed whole or divided.

Serious adverse events include rhabdomyolysis, severe liver injury, pancreatitis, and rare allergic reactions. Patients should promptly report unexplained muscle pain, dark urine, jaundice, or signs of an allergic response to their healthcare provider.

Lipanthyl Supra is contraindicated in patients with known hypersensitivity to fenofibrate or any component of the formulation, severe liver disease, and in individuals with active gallbladder disease. Clinicians should also exercise caution in patients with renal impairment.